{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:39:02Z","timestamp":1770277142239,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bortezomib, a proteasome inhibitor, proved potent in the treatment of recurrent multiple myeloma or mantle cell lymphoma. However, slow progress was made when it was applied to treat solid tumors. We discovered that different head and neck squamous cell carcinoma (HNSCC) cell lines had significantly different sensitivities to bortezomib, and also demonstrated that individual relatively sensitive HNSCC cell lines had fewer \u0394Np63\u03b1 expressions. Based on these findings, we speculated that \u0394Np63\u03b1 may be a key factor in the resistance of HNSCC cells to bortezomib. \u0394Np63\u03b1 knockdown made HNSCC more sensitive to bortezomib, while \u0394Np63\u03b1 overexpression made it more resistant. RNA sequencing (RNA-seq) analysis of \u0394Np63\u03b1-knockdown cells revealed clear alterations in the subset of genes that were associated with oxidative stress and antioxidant defense. The gene CYGB was downregulated significantly. CHIP-seq detection showed that CYGB was the transcriptional regulatory site of \u0394Np63\u03b1. CHIP-PCR showed evidence of \u0394Np63\u03b1 binding. The detection of the dual-luciferase reporter gene demonstrated that \u0394Np63\u03b1 significantly enhanced the CYGB promoter activity. Furthermore, we confirmed that CYGB plays a role in clearing excess ROS induced by bortezomib to inhibit HNSCC apoptosis. Consequently, \u0394Np63\u03b1 regulated the expression of CYGB in HNSCC. CYGB was the target of transcription regulation of \u0394Np63\u03b1. It reduced apoptosis by clearing excess ROS produced by bortezomib, and thus exerted drug resistance.<\/jats:p>","DOI":"10.1038\/s41419-022-04790-0","type":"journal-article","created":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T14:02:54Z","timestamp":1649512974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["\u0394Np63\u03b1 promotes Bortezomib resistance via the CYGB\u2013ROS axis in head and neck squamous cell carcinoma"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0890-5392","authenticated-orcid":false,"given":"Peng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianmin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dadong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3859-7506","authenticated-orcid":false,"given":"Minhui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-9347","authenticated-orcid":false,"given":"Hongliang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,9]]},"reference":[{"key":"4790_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA: A Cancer J Clin"},{"key":"4790_CR2","unstructured":"Network NCC. NCCN Clinical Practice Guidelines in Oncology 2019 Head and Neck Cancers v3. Plymouth Meeting, PA: National Comprehensive Cancer Network 2019."},{"key":"4790_CR3","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1158\/1078-0432.CCR-03-0781","volume":"10","author":"PF Bross","year":"2004","unstructured":"Bross PF, Kane R, Farrell AT, Abraham S, Pazdur R. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res. 2004;10:3954\u201364.","journal-title":"Clin Cancer Res"},{"key":"4790_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1586\/era.13.9","volume":"13","author":"JJOR Shah","year":"2013","unstructured":"Shah JJOR. Proteasome inhibitors in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2013;13:339\u201358.","journal-title":"Expert Rev Anticancer Ther"},{"key":"4790_CR5","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3324\/haematol.2011.051169","volume":"96","author":"JF San-Miguel","year":"2011","unstructured":"San-Miguel JF, Mateos MV. Can multiple myeloma become a curable disease? Haematologica. 2011;96:1246\u20138.","journal-title":"Haematologica."},{"key":"4790_CR6","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1128\/MCB.23.7.2264-2276.2003","volume":"23","author":"MD Westfall","year":"2003","unstructured":"Westfall MD, Mays DJ, Sniezek JC, Pietenpol JAJM, Biology C. The \u0394Np63\u03b1 phosphoprotein binds the p21 and 14-3-3\u03c3 promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol. Cell. Biol. 2003;23:2264\u201376.","journal-title":"Mol. Cell. Biol"},{"key":"4790_CR7","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1097\/01.mlg.0000149437.35855.4b","volume":"114","author":"JC Sniezek","year":"2010","unstructured":"Sniezek JC, Matheny KE, Westfall MD. Pietenpol JAJTL Dominant negative p63 Isoform expression in head and neck squamous cell carcinoma. Laryngoscope 2010;114:2063\u201372.","journal-title":"Laryngoscope"},{"key":"4790_CR8","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1038\/sj.onc.1206536","volume":"22","author":"KE King","year":"2003","unstructured":"King KE, Ponnamperuma RM, Yamashita T, Tokino T, Weinberg WCJO. deltaNp63alpha functions as both a positive and a negative transcriptional regulator and blocks in vitro differentiation of murine keratinocytes. Oncogene. 2003;22:3635\u201344.","journal-title":"Oncogene."},{"key":"4790_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.crvi.2008.07.026","volume":"332","author":"H Wajcman","year":"2009","unstructured":"Wajcman H, Kiger L, Marden MCJCRB. Structure and function evolution in the superfamily of globins. C R Biol. 2009;332:273\u201382.","journal-title":"C R Biol"},{"key":"4790_CR10","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s11064-007-9317-x","volume":"32","author":"LCX Dan","year":"2007","unstructured":"Dan LCX, Li W-J, Yang Y-H, Wang J-Z, Yu ACH. Cytoglobin up-regulated by hydrogen peroxide plays a protective role in oxidative stress. Neurochem Res. 2007;32:1375\u201380.","journal-title":"Neurochem Res"},{"key":"4790_CR11","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3181\/0903-RM-98","volume":"234","author":"PJ Chua","year":"2009","unstructured":"Chua PJ, Yip GW-C, Bay BH. Cell cycle arrest induced by hydrogen peroxide is associated with modulation of oxidative stress related genes in breast cancer cells. Exp Biol Med. 2009;234:1086\u201394.","journal-title":"Exp Biol Med"},{"key":"4790_CR12","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.ymthe.2005.11.027","volume":"13","author":"R Xu","year":"2006","unstructured":"Xu R, Harrison P, Chen M, Li L, Tsui T, Fung P, et al. Cytoglobin overexpression protects against damage-induced fibrosis. Mol Ther. 2006;13:1093\u2013100.","journal-title":"Mol Ther"},{"key":"4790_CR13","doi-asserted-by":"publisher","first-page":"F1120","DOI":"10.1152\/ajprenal.00145.2010","volume":"299","author":"I Mimura","year":"2010","unstructured":"Mimura I, Nangaku M, Nishi H, Inagi R, Tanaka T, Fujita T. Cytoglobin, a novel globin, plays an antifibrotic role in the kidney. Ajp Ren Physiol. 2010;299:F1120\u201333.","journal-title":"Ajp Ren Physiol"},{"key":"4790_CR14","doi-asserted-by":"publisher","first-page":"7856","DOI":"10.1074\/jbc.M512655200","volume":"281","author":"W Yan","year":"2006","unstructured":"Yan W, Chen X. GPX2, a direct target of p63, inhibits oxidative stress-induced apoptosis in a p53-dependent manner. J Biol Chem. 2006;281:7856\u201362.","journal-title":"J Biol Chem"},{"key":"4790_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/sj.bjc.6602972","volume":"94","author":"RJ Shaw","year":"2006","unstructured":"Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, Lowe D, et al. Promoter methylation of P16, RAR\u03b2, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br J Cancer. 2006;94:561\u20138.","journal-title":"Br J Cancer"},{"key":"4790_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-1-4615-0081-0_5","volume":"532","author":"M Esteller","year":"2003","unstructured":"Esteller M. Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv Exp Med Biol. 2003;532:39\u201349.","journal-title":"Adv Exp Med Biol"},{"key":"4790_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1001\/archoto.2007.50","volume":"134","author":"RJ Shaw","year":"2008","unstructured":"Shaw RJ, Hall GL, Lowe D, Liloglou T, Field JK, Sloan P, et al. The role of pyrosequencing in head and neck cancer epigenetics. Arch Otolaryngol\u2013head. 2008;134:251\u20136.","journal-title":"Arch Otolaryngol\u2013head"},{"key":"4790_CR18","doi-asserted-by":"publisher","first-page":"33714","DOI":"10.1074\/jbc.M302559200","volume":"278","author":"YH Ling","year":"2003","unstructured":"Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem. 2003;278:33714\u201323.","journal-title":"J Biol Chem"},{"key":"4790_CR19","first-page":"2615","volume":"59","author":"J Adams","year":"1999","unstructured":"Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615\u201322.","journal-title":"Cancer Res"},{"key":"4790_CR20","first-page":"3204","volume":"7","author":"BA Catherine","year":"2016","unstructured":"Catherine BA, Gittler MP, Charles JP, Niklas G, Ines E, Marco M, et al. Np63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinoma. Nucleic Acids Res. 2016;7:3204\u201318.","journal-title":"Nucleic Acids Res"},{"key":"4790_CR21","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.4161\/cc.7.18.6627","volume":"7","author":"Y Huang","year":"2008","unstructured":"Huang Y, Sen T, Nagpal J, Upadhyay S, Trink B, Ratovitski E, et al. ATM kinase is a master switch for the Delta Np63 alpha phosphorylation\/degradation in human head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle. 2008;7:2846\u201355.","journal-title":"Cell Cycle"},{"key":"4790_CR22","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1038\/cdd.2010.188","volume":"18","author":"Y Huang","year":"2011","unstructured":"Huang Y, Chuang A, Hao H, Talbot C, Sen T, Trink B, et al. Phospho-\u0394Np63\u03b1 is a key regulator of the cisplatin-induced microRNAome in cancer cells. Cell Death Differ. 2011;18:1220\u201330.","journal-title":"Cell Death Differ"},{"key":"4790_CR23","first-page":"494","volume":"8","author":"C Como","year":"2002","unstructured":"Como C, Urist MJ, Babayan I, Drobnjak M, Cordon-Cardo C. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res. 2002;8:494\u2013501.","journal-title":"Clin Cancer Res"},{"key":"4790_CR24","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.1073\/pnas.97.10.5462","volume":"97","author":"K Hibi","year":"2000","unstructured":"Hibi K, Trink B, Patturajan M, Westra WH, L.Caballero OV, Hill DE, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA. 2000;97:5462\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4790_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03470-y","volume":"9","author":"P Arcidiacono","year":"2018","unstructured":"Arcidiacono P, Webb CM, Brooke MA, Zhou H, Delaney PJ, Ng KE, et al. p63 is a key regulator of iRHOM2 signalling in the keratinocyte stress response. Nat Commun. 2018;9:1021.","journal-title":"Nat Commun"},{"key":"4790_CR26","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1097-2765(02)00706-2","volume":"10","author":"LW Ellisen","year":"2002","unstructured":"Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Min Da K, et al. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell. 2002;10:995\u20131005.","journal-title":"Mol Cell"},{"key":"4790_CR27","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.yexcr.2004.02.001","volume":"295","author":"C Yu","year":"2004","unstructured":"Yu C, Rahmani M, Dent P, Grant S. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp Cell Res. 2004;295:555\u201366.","journal-title":"Exp Cell Res"},{"key":"4790_CR28","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.1038\/srep05896","volume":"4","author":"S Maharjan","year":"2014","unstructured":"Maharjan S, Oku M, Tsuda M, Hoseki J, Sakai Y. Mitochondrial impairment triggers cytosolic oxidative stress and cell death following proteasome inhibition. Sci Rep. 2014;4:5896.","journal-title":"Sci Rep"},{"key":"4790_CR29","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.freeradbiomed.2008.08.002","volume":"45","author":"S Vali","year":"2008","unstructured":"Vali S, Chinta SJ, Peng J, Sultana Z, Singh N, Sharma P, et al. Insights into the effects of alpha-synuclein expression and proteasome inhibition on glutathione metabolism through a dynamic in silico model of Parkinson\u2019s disease: validation by cell culture data. Free Radic Biol Med. 2008;45:1290\u2013301.","journal-title":"Free Radic Biol Med"},{"key":"4790_CR30","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s10495-007-0069-5","volume":"12","author":"L Papa","year":"2007","unstructured":"Papa L, Gomes E, Rockwell P. Reactive oxygen species induced by proteasome inhibition in neuronal cells mediate mitochondrial dysfunction and a caspase-independent cell death. Apoptosis. 2007;12:1389\u2013405.","journal-title":"Apoptosis."},{"key":"4790_CR31","doi-asserted-by":"publisher","first-page":"9695","DOI":"10.1128\/MCB.24.22.9695-9704.2004","volume":"24","author":"A F Ribley","year":"2004","unstructured":"F Ribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol. 2004;24:9695\u2013704.","journal-title":"Mol Cell Biol"},{"key":"4790_CR32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.gene.2007.03.022","volume":"398","author":"E Fordel","year":"2007","unstructured":"Fordel E, Thijs L, Martinet W, Schrijvers D, Moens L, Dewilde S. Anoxia or oxygen and glucose deprivation in SH-SY5Y cells: a step closer to the unraveling of neuroglobin and cytoglobin functions. Gene 2007;398:114\u201322.","journal-title":"Gene"},{"key":"4790_CR33","doi-asserted-by":"publisher","first-page":"25318","DOI":"10.1074\/jbc.M102630200","volume":"276","author":"NKDAK Kawada","year":"2001","unstructured":"Kawada NKDAK, Nakatani K, Minamiyama Y, Seki S, Yoshizato K. Characterization of a stellate cell activation-associated protein (STAP) with peroxidase activity found in rat hepatic stellate cells. J Biol Chem. 2001;276:25318\u201323.","journal-title":"J Biol Chem"},{"key":"4790_CR34","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.jinorgbio.2008.05.008","volume":"102","author":"MGP A","year":"2008","unstructured":"A MGP, B SD, A AF. Reactions of ferrous neuroglobin and cytoglobin with nitrite under anaerobic conditions. J Inorg Biochem. 2008;102:1777\u201382.","journal-title":"J Inorg Biochem"},{"key":"4790_CR35","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1593\/neo.08456","volume":"10","author":"O Genin","year":"2008","unstructured":"Genin O, Rechavi G, Nagler A, Ben-Itzhak O, Nazemi KJ, Pines M. Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma: a novel target for treatment? Neoplasia. 2008;10:940\u20138.","journal-title":"Neoplasia."},{"key":"4790_CR36","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1093\/hmg\/ddl128","volume":"15","author":"G Xinarianos","year":"2006","unstructured":"Xinarianos G, Mcronald FE, Risk JM, Bowers NL, Nikolaidis G, Field JK, et al. Frequent genetic and epigenetic abnormalities contribute to the deregulation of cytoglobin in non-small cell lung cancer. Hum Mol Genet. 2006;15:2038\u201344.","journal-title":"Hum Mol Genet"},{"key":"4790_CR37","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mc.20096","volume":"43","author":"N Presneau","year":"2005","unstructured":"Presneau N, Dewar K, Forgetta V, Provencher D, Mes-Masson AM, Tonin PN. Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1\u2010q25.2. Mol Carcinogenesis. 2005;43:141.","journal-title":"Mol Carcinogenesis"},{"key":"4790_CR38","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/hmg\/ddl042","volume":"15","author":"FE Mcronald","year":"2006","unstructured":"Mcronald FE, Liloglou T, Xinarianos G, Hill L, Rowbottom L, Langan JE, et al. Down-regulation of the cytoglobin gene, located on 17q25, in tylosis with oesophageal cancer (TOC): evidence for trans-allele repression. Hum Mol Genet. 2006;15:1271\u20137.","journal-title":"Hum Mol Genet"},{"key":"4790_CR39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000078011","volume":"105","author":"S Wystub","year":"2003","unstructured":"Wystub S, Ebner B, Fuchs C, Weich B, Burmester T, Hankeln T. Interspecies comparison of neuroglobin, cytoglobin and myoglobin: sequence evolution and candidate regulatory elements. Cytogenetic Genome Res. 2003;105:65\u201378.","journal-title":"Cytogenetic Genome Res"},{"key":"4790_CR40","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbaexp.2006.04.002","volume":"1759","author":"X Guo","year":"2006","unstructured":"Guo X, Philipsen S, Tanun K. Characterization of human cytoglobin gene promoter region. BBA - Gene Struct Expr. 2006;1759:208\u201315.","journal-title":"BBA - Gene Struct Expr"}],"updated-by":[{"DOI":"10.1038\/s41419-022-04870-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000}}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04790-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04790-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04790-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T15:01:00Z","timestamp":1669302060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04790-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,9]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["4790"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-04790-0","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41419-022-04870-1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,9]]},"assertion":[{"value":"23 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41419-022-04870-1","URL":"https:\/\/doi.org\/10.1038\/s41419-022-04870-1","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal studies were conducted with approval from the Animal Research Ethics Committee of Changhai Hospital of China and performed in accordance with established guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"327"}}